Neogenomics (NEO) Income towards Parent Company (2016 - 2025)
Historic Income towards Parent Company for Neogenomics (NEO) over the last 17 years, with Q4 2025 value amounting to -$9.9 million.
- Neogenomics' Income towards Parent Company rose 3551.94% to -$9.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$108.0 million, marking a year-over-year decrease of 3721.64%. This contributed to the annual value of -$108.0 million for FY2025, which is 3721.64% down from last year.
- As of Q4 2025, Neogenomics' Income towards Parent Company stood at -$9.9 million, which was up 3551.94% from -$27.1 million recorded in Q3 2025.
- Over the past 5 years, Neogenomics' Income towards Parent Company peaked at $75.9 million during Q2 2021, and registered a low of -$49.4 million during Q1 2022.
- For the 5-year period, Neogenomics' Income towards Parent Company averaged around -$21.4 million, with its median value being -$23.5 million (2022).
- The largest annual percentage gain for Neogenomics' Income towards Parent Company in the last 5 years was 121185.52% (2021), contrasted with its biggest fall of 89577.63% (2021).
- Neogenomics' Income towards Parent Company (Quarter) stood at -$41.8 million in 2021, then surged by 45.67% to -$22.7 million in 2022, then skyrocketed by 36.85% to -$14.3 million in 2023, then fell by 6.97% to -$15.3 million in 2024, then skyrocketed by 35.52% to -$9.9 million in 2025.
- Its Income towards Parent Company was -$9.9 million in Q4 2025, compared to -$27.1 million in Q3 2025 and -$45.1 million in Q2 2025.